Paridiprubart
As of the edition of 20 October 2026, Paridiprubart is an antibody: in active development; acts on TLR4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 4, 0 stopped early
- Disease areas
- Lungs and airways; Bones, joints and muscles; Immune system; Infections; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Paridiprubart.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TLR4 | Toll-like receptor 4 | O00206 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 1 | 2 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Light Chain Bioscience - | Lead sponsor of trials | 2017 to now |
| Edesa Biotech | Lead sponsor of trials | 2020 to now |